Important Safety Information
Semaglutide injection
Boxed Warning
Ozempic (semaglutide) causes thyroid C-cell tumors in rodents at clinically relevant exposures. It is unknown whether Ozempic causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans. Ozempic is contraindicated in patients with a personal or family history of MTC and in patients with MEN 2.
Ozempic® (semaglutide) injection is FDA-approved to improve blood sugar in adults with type 2 diabetes and to reduce the risk of major cardiovascular events in adults with type 2 diabetes and known heart disease. Use for weight loss is off-label and is at the discretion of your prescribing provider.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity, or overweight in the presence of at least one weight-related condition.
Semaglutide may cause serious side effects, including:
The most common side effects of semaglutide may include:
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to the manufacturer or to your NowYou care team.
This summary does not include all information about this medication. It is not a substitute for the full Prescribing Information or for talking with your healthcare provider. Please read the full Prescribing Information and Medication Guide before starting treatment, and discuss any questions with your provider.
Always read the full Prescribing Information and Medication Guide before starting treatment.
This safety summary is provided for educational purposes and does not replace the full Prescribing Information, Medication Guide, or professional medical advice. Always discuss benefits, risks, and alternatives with your licensed provider.